1.Extended adjuvant temozolomide for treatment of glioblastoma multiforme:experience of a single institu- tion
Changguo SHAN ; Mingyao LAI ; Weiping HONG ; Junjie ZHEN ; Qingjun HU ; Xuebing LING ; Linbo CAI
The Journal of Practical Medicine 2017;33(16):2743-2746
Objective To assess the impact of additional cycles of temozolomide on the survival of glio-blastoma(GBM)patients after 6 months of maintenance temozolomide(TMZ)following concurrent TMZ chemo-therapy and radiation therapy. Methods Data of 51 GBM patients from 2009 to 2015 were retrospectively studied and the therapeutic effect was assessed according to whether receiving long-term treatment with TMZ. Results Sev-enteen of fifty-one GBM patients received 8 or more cycles and prolonged treatment improved progression-free sur-vival(P=0.011)and overall survival(P=0.004). Conclusions Extended use of TMZ is safe to GBM patients , which may improve response OS and PFS compared to conventional regimen. Prospective studies in larger popula-tions are needed to better-define the population to whom it can be proposed and its optimal duration.
2.Comparison of the efficacy and safety of concurrent chemoradiotherapy and sequential chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer
Mingyao LI ; Zhenfei XIANG ; Jinguo WANG ; Danfei HU ; Yangfang LU
Chinese Journal of Primary Medicine and Pharmacy 2019;26(7):868-872
Objective To comparO thO Officacy and safOty of concurrOnt chOmoradiothOrapy and sOquOntial chOmoradiothOrapy in thO trOatmOnt of locally advancOd non -small cOll lung cancOr ( NSCLC). Methods From SOptOmbOr 2016 to FObruary 2018, 88 patiOnts with locally advancOd NSCLC admittOd to Li Huili East Hospital wOrO randomly dividOd into synchronous group ( 45 casOs) and sOquOntial group ( 43 casOs). ThO synchronous group rOcOivOd concurrOnt radiothOrapy and chOmothOrapy, whilO thO sOquOntial group was givOn radiothOrapy aftOr 4 cyclOs of chOmothOrapy. Both two groups took thO samO radiothOrapy and chOmothOrapy prOscription. ThO clinical Officacy, advOrsO rOactions and quality of lifO of thO two groups wOrO comparOd.Results ThO total OffOctivO ratO in thO synchro-nous group was significantly highOr than that in thO sOquOntial group (6.22% vs. 39.53% , χ2 =4.530,P<0.05). ThO incidOncO ratO of Ⅰ ~Ⅱ gradO radiation lung injury and radiation Osophagitis in thO synchronous group wOrO significantly highOr than thosO in thO sOquOntial group (26.67% vs. 9.30% ;17.78% vs. 2.32% , χ2 =4.457, 4.159,all P<0.05).ThOrO was no statistically significant diffOrOncO in quality of lifO scorO bOtwOOn thO two groups bOforO trOatmOnt (P>0.05).ThO body hOalth and total hOalth status of thO synchronous group wOrO significantly lowOr than thosO of thO sOquOntial group at thO Ond of trOatmOnt [(66.48 ± 9.28) points vs.(70.95 ± 11.68) points;(51.48 ± 10.26)points vs.(55.42 ± 9.84)points, t=2.010,2.144,all P<0.05], but thO scorO of total hOalth status in thO synchronous group was significantly highOr than that in thO sOquOntial group at thO Ond of trOatmOnt [(61.28 ± 6.48)points vs.(57.83 ± 7.93)points, t=2.239,P<0.05].Conclusion ConcurrOnt chOmoradiothOrapy has bOttOr clinical Officacy than sOquOntial radiothOrapy and chOmothOrapy in thO trOatmOnt of locally advancOd NSCLC. Although it can incrOasO thO incidOncO of radiation pnOumonitis and Osophagitis, thO patiOnts arO wOll tolOratOd and thO quality of lifO is improvOd gradually at thO Ond of thO trOatmOnt. It is worthy of clinical promotion.
3.Risk factors of delayed bleeding after endoscopic submucosal dissection for early colorectal cancer and pre-cancerous lesions
Hongbo WANG ; Miao LIU ; Mingyao XU ; Yin GUO ; Xia PAN ; Junjie HU ; Qingbo CHEN
The Journal of Practical Medicine 2018;34(6):978-981,986
Objective To investgate risk factors of delayed bleeding after endoscopic submucosal dissec-tion(ESD)for early colorectal tumor and precancerrous lesions. Methods We retrospectively reviewed clinical date of 138 patients with early colorectal tumor and precancerrous lesions who received ESD in Hubei Cancer Hos-pital from October 2012 to October 2016. Risk factors of delayed bleeding were analysed by univariate and multi-variable logistic regression analysis. Results Ten(7.2%)of 138 patients occurred delayed bleeding after ESD. Univariate analysis showed that there was significent difference between the bleeding group and the non-bleeding group in location of the lesion(P = 0.022),severe fibrosis of submucosa(P = 0.016),Obvious intraoperative bleeding(P = 0.032)and inadequate endosopic experience of endoscopist(P = 0.045). Multivariate Logistic re-gression analysis showed that location of lesion(P = 0.003,OR = 4.64,95%CI:1.71~12.58),severe fibrosis of submucosa(P = 0.009,OR = 4.83,95% CI:1.49~15.60)were independent risk factors of delayed bleeding after ESD for early colorectal tumor and precancerrous lesions. Conclusion Patients with early colorectal tumor and precancerrous lesions in the rectum and severe fibrosis of submucosa are prone to delayed bleeding after ESD.
4.Clinicopathological features for epithelioid glioblastoma:A newly defined tumor by the 2016 World Health Organization Classification of Tumors of the Central Nervous System
Juan LI ; Xuebing LING ; Mingyao LAI ; Qingjun HU ; Changguo SHAN ; Linbo CAI
Journal of Central South University(Medical Sciences) 2018;43(4):398-402
Objective:To retrospectively summarize the clinicopathological features of epithelioid glioblastoma (Ep-GBM) and to explore new treatment for Ep-GBM.Methods:The clinical data of 13 patients with Ep-GBM,who were treated in our department from March 2016 to July 2017,were retrospectively analyzed.The clinicopathological features were summarized and the efficacy was evaluated.Results:The positive rate of BRAFV600E mutant and INI-1 was 76.9% (10/13) and 80% (8/10),respectively,while the median Ki-67 index was 30%.Meningeal metastases occurred in 9 cases (69.7%) during the course.The median follow-up time was 12 (6-25) months,and the median progression-free time was 8.6 (2.2-16.5) months.Three patients died and the 1-year overall survival rate was 54%.Conclusion:Ep-GBM has a high degree of malignancy and is prone to spread to leptomeninges.INI-1 expression and BRAFV600E mutation are common for Ep-GBM.BRAF inhibitor might be a potential therapeutic drug for it.
5.Preoperative left ventricular ejection fraction and risk for postoperative major adverse cardiovascular events in elderly patients with hip fracture
Mingyao SUN ; Man LI ; Sanbao HU
Chinese Journal of Orthopaedic Trauma 2023;25(9):785-791
Objective:To investigate the relationship between preoperative left ventricular ejection fraction (LVEF) and the risk for postoperative major adverse cardiovascular events (MACE) in elderly patients with hip fracture.Methods:A retrospective study was conducted to analyze the data of 403 elderly patients with hip fracture who had undergone surgical treatment at Department of Orthopedics, Beijing Anzhen Hospital from January 2015 to January 2021. Gender: 118 males and 285 females; age: 80 (74, 85) years; fracture type: 228 femoral neck fractures and 175 intertrochanteric (including subtrochanteric) fractures. Cardiovascular disease was complicated in 161 patients before surgery. The incidence of MACE within 30 days after surgery was statistically analyzed. The patients were divided into 2 groups according to whether MACE occurred 30 days after surgery: an MACE group and a non-MACE group. The baseline data, LVEF, preoperative cardiovascular complications, American Society of Anesthesiologists(ASA) grading and other indicators were compared between the 2 groups. Based on patient sample analysis, the receiver operating characteristic curve (ROC) was plotted to determine the optimal cutoff value of preoperative LVEF, according to which the relationship was analyzed between preoperative LVEF and the risk for postoperative MACE.Results:The overall incidence of postoperative MACE was 12.4% (50/403). There were statistically significant differences between the MACE group and the non-MACE group in preoperative LVEF[60.0% (56.0%, 63.0%) versus 62.0% (60.0%, 65.0%)], preoperative cardiovascular complications[74.0% (37/50) versus 35.1% (124/353)] and ASA grade ≥3[90.0% (45/50) versus 74.8% (264/353)]. ROC analysis showed that LVEF=60% was the optimal threshold for prediction of postoperative MACE (area under curve=0.680, sensitivity 48.0%, and specificity 83.0%). Multivariate logistic regression analysis showed that LVEF<60% and preoperative cardiovascular disease were risk factors for postoperative MACE. Subgroup analysis showed that the incidence of MACE in patients with LVEF<60% was significantly higher than that in patients with LVEF≥60% regardless of preoperative cardiovascular disease ( P<0.05). Conclusion:Preoperative LVEF<60% is a risk factor for postoperative MACE in elderly patients with hip fracture.
6.Exposure difference of various dosage forms of mycophenolic acid in different age groups of pediatric kidney transplantation
Jie ZHANG ; Fumin CHENG ; Kunlun ZHU ; Mingyao HU ; Wenjun SHANG ; Guiwen FENG
Organ Transplantation 2022;13(3):356-
Objective To investigate the exposure difference of different dosage forms of mycophenolic acid (MPA) between children aged ≤12 and > 12 years old after kidney transplantation. Methods Clinical data of 73 children undergoing kidney transplantation from donation after cardiac death (DCD) were retrospectively analyzed. Postoperative immunosuppressive regimen was MPA+ tacrolimus+glucocorticoid. According to different dosage forms of MPA, all recipients were divided into group A (
7. Progresses in pharmaceutical and surgical management of premature ejaculation
Qin-Bo HU ; Dong ZHANG ; Liang MA ; Derry Mingyao NG ; Maria HALEEM ; Qi MA
Chinese Medical Journal 2019;132(19):2362-2372
Objective:
Premature ejaculation (PE) is regarded as one of the most common male sexual dysfunctions. This review introduced several pharmaceutical and surgical methods for the management of PE. The definition, etiology, behavioral, and psychological therapy of PE were also discussed.
Data sources:
"Premature," "ejaculation," or "sexual dysfuction" were used as the medical subject headings (MeSH) to obtain relevant articles before June 2019 on Pubmed, Google Scholar and CNKI. Most articles used were written in English and several Chinese articles were also cited.
Study selection:
Full-text articles of retrospective/prospective/randomized controlled trials were analyzed. Animal experiments and letters were excluded.
Results:
There are four PE sub-types: lifelong PE, acquired PE, natural variable PE, and subjective PE. Behavioral therapy, psychotherapy, medication, topical anesthetics, and surgery are currently used for the treatment of PE. However, all the above treatments have limitations. Therefore, novel ways should be investigated to more efficiently control PE.
Conclusions
The pharmaceutical therapy that is currently being used in clinical practice for the management of PE is still the main choice globally due to its good efficacy. Surgery may be a choice for patients who are resistant to medication. However, it should be performed cautiously.
8.Correction to: Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants.
Lei YANG ; Xiaohui ZHANG ; Liren WANG ; Shuming YIN ; Biyun ZHU ; Ling XIE ; Qiuhui DUAN ; Huiqiong HU ; Rui ZHENG ; Yu WEI ; Liangyue PENG ; Honghui HAN ; Jiqin ZHANG ; Wenjuan QIU ; Hongquan GENG ; Stefan SIWKO ; Xueli ZHANG ; Mingyao LIU ; Dali LI
Protein & Cell 2019;10(9):700-700
In the original publication the grant number is incorrectly published. The correct grant number should be read as "17140901600". The corrected contents are provided in this correction article. This work was partially supported by grants from the National Natural Science Foundation of China (Nos. 81670470 and 81600149), a grant from the Shanghai Municipal Commission for Science and Technology (17140901600, 18411953500 and 15JC1400201) and a grant from National Key Research and Development Program (2016YFC0905100).
9.Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants.
Lei YANG ; Xiaohui ZHANG ; Liren WANG ; Shuming YIN ; Biyun ZHU ; Ling XIE ; Qiuhui DUAN ; Huiqiong HU ; Rui ZHENG ; Yu WEI ; Liangyue PENG ; Honghui HAN ; Jiqin ZHANG ; Wenjuan QIU ; Hongquan GENG ; Stefan SIWKO ; Xueli ZHANG ; Mingyao LIU ; Dali LI
Protein & Cell 2018;9(9):814-819